In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Diana Kraskouskaya, co-founder and CEO of Dalriada.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Diana, covering:
- Exactly what ‘the Toronto paradox’ is…
- How two, seed-funded failures, led to identifying a gap in the market along with access to a rich talent pool
- The challenges and realities of starting, growing and scaling a CRO business to over 100 people
- Advice for other females looking to forge an entrepreneurial career in the drug development space
Diana brings years of leadership and hands-on cross-disciplinary biotech and drug discovery experience spanning areas of company building, scientific & IP program strategy, and operations.
She completed an Honors BSc Degree in Molecular Biology and PhD in Medicinal Chemistry from the University of Toronto and is a co-founder of two other biotechs, which have raised > $10 M in VC funding. Diana is the recipient of several entrepreneurship awards, including the RBC Prize for Innovation & Entrepreneurship and the 2018 MNP Future Leaders Awards.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.